Condition
Pneumocystis Jiroveci Pneumonia
Total Trials
4
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 80/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
P 2 (1)
P 3 (1)
P 4 (1)
Trial Status
Not Yet Recruiting2
Terminated1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07328984Phase 4Not Yet Recruiting
How Long Should we Give Steroids for Patients With Severe PCP
NCT07152613Phase 3Not Yet RecruitingPrimary
Corticosteroids for PJP in Non-HIV Immunocompromised Adults
NCT00080119Phase 2Terminated
Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV
NCT03201497UnknownPrimary
Prospective Registration of Severe Pneumocystis Jiroveci Pneumonia Requiring ICU Admission
Showing all 4 trials